Subscribe
Share
Share
Embed
India's FSSAI issues notices to Nestlé and Unilever over misleading health claims, while Quartz audits evidence behind 10 popular supplements.
India's regulator is formally accusing Nestlé and Unilever of misleading health claims — a warning shot every supplement and functional food marketer should hear. Plus: a brain health finding that could reshape cognitive supplement positioning.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: There's a lot on the table today.
Klara: We're looking at India's food regulator going after Nestlé and Unilever for misleading health claims — and what that signals for European marketers.
Marco: Then a genuinely interesting brain health finding out of Japan, a big evidence review of ten popular supplements, and a lesson in brand storytelling from the founders of Bala and Therabody.
Klara: Let's get into it.
Marco: India's food regulator has formally accused Nestlé and Hindustan Unilever of making misleading health claims on their products.
Marco: These are two of the biggest food and consumer goods companies on the planet. Both are deeply invested in health and wellness positioning. When a regulator goes after names this large, the whole industry pays attention.
Marco: India's FSSAI — that's the Food Safety and Standards Authority of India — has issued official notices to both companies. The details of the specific claims involved are still emerging, but the direction of travel is clear. Regulators in major markets are losing patience with vague, unsubstantiated health messaging.
Klara: This mirrors exactly what we've seen from EFSA in Europe over the past decade. EFSA — the European Food Safety Authority — has rejected the vast majority of health claims submitted to it, precisely because the science behind them wasn't strong enough. The standard here is EC 1924/2006, the EU regulation that governs what you can and cannot say about food and nutrition. It's strict, and it exists for a reason.
Marco: Commercially, I'd argue brands have leaned too hard on wellness language as a positioning shortcut. "Supports immunity." "Promotes gut health." These phrases travel across markets with very little scrutiny applied. That era is ending.
Klara: I'd push back slightly on the framing that this is purely new. Regulators have always had this authority. What's changed is enforcement appetite. And when you see coordinated pressure across markets — India, the EU, the UK — it becomes very hard for a global brand to maintain one standard of evidence here and a looser one elsewhere.
Marco: One claims strategy, evidenced to the highest applicable standard. That's not a burden — that's protection.
Marco: Now, let's move to our next story.
Klara: Japanese researchers have found a natural compound that may protect the brain from the cognitive damage caused by eating too much salt.
Klara: Most people know high salt intake is bad for the heart and blood pressure. What's less understood is that excess sodium also appears to harm the brain directly — affecting memory and how we interact socially. This study adds a neurological dimension to a risk factor that's already firmly on the public health radar.
Klara: The research, conducted in experimental models, showed that excessive salt consumption impaired both memory and social behaviour — independently of blood pressure effects. Crucially, the team identified a natural compound that could protect against those specific cognitive deficits. The compound itself hasn't been named in the public summary yet, and we're still at the animal model stage. No human trial data exists at this point.
Klara: From a science standpoint, the separation between cardiovascular and cognitive harm is the genuinely interesting part. It suggests there may be a distinct neurological mechanism at play — one that could, in principle, be targeted through supplementation. But I want to be clear: animal models don't translate automatically to human outcomes. Before any brand puts this on a label, we'd need human clinical evidence and, in Europe, a credible path through EFSA's authorisation process for any associated health claim.
Marco: I take that point entirely, but from a formulation and positioning perspective, this is worth tracking closely. Cognitive health is growing fast across European markets — UK, Germany, Nordics especially. A natural compound framed around everyday dietary risk, something as relatable as salt intake, gives brands a much more accessible consumer narrative than abstract nootropic language.
Klara: That relatability cuts both ways, though. The more mainstream the hook, the more regulatory scrutiny it attracts.
Marco: Agreed — which means the brands who invest in the clinical pipeline now will be the ones with a defensible position when this matures. Watch this ingredient space carefully.
Marco: Let's move to our next story.
Marco: Quartz has just published a detailed, consumer-facing audit of the clinical evidence behind ten of the most popular supplements on the market.
Marco: This matters because mainstream media coverage shapes buyer behaviour. When a respected outlet tells everyday consumers which supplements have solid science and which ones don't, it shifts how people shop. It also puts brands on notice.
Marco: The Quartz piece draws a clear line between supplements backed by robust evidence and those where the marketing has run well ahead of the science. On the same day, they published a companion piece highlighting supplement categories that routinely fail independent lab testing — meaning the product on shelf doesn't match what's on the label. Together, these two pieces represent a level of mainstream scrutiny the sector hasn't seen in a while.
Klara: From a science perspective, the distinction they're drawing is exactly right. There are supplements with genuinely strong clinical backing — certain vitamin D formulations, omega-3s in specific contexts, magnesium. And then there are categories where the evidence is thin, mixed, or entirely absent. The problem is that on shelf, everything looks equally credible. Packaging doesn't tell you that story.
Marco: Commercially, this is an inflection point. European consumers are already more sceptical than their US counterparts. Add a high-profile evidence review to the broader wave of regulatory tightening we've been discussing today, and you have a market that's moving fast toward demanding proof.
Klara: Where I'd push the conversation further is on the lab-testing angle. A product can have good underlying science and still fail on quality grounds if the manufacturer hasn't invested in third-party verification. Those are two separate problems, and brands need to address both.
Marco: Which means the transparency argument isn't optional anymore — it's the baseline. Right, let's move to our final story.
Klara: The founders of two major wellness hardware brands have gone public with their personal anti-burnout strategies — and it's become a marketing story worth examining.
Klara: Bala and Therabody are not niche players. Bala turned weighted fitness accessories into a lifestyle aesthetic. Therabody built a global category around percussive therapy devices. Both brands carry serious commercial weight, and both are built on a very specific promise: that physical wellness is achievable and aspirational.
Klara: At the Inc. 5000 conference, Natalie Holloway of Bala and Dr. Jason Wersland of Therabody each spoke openly about the behavioural trade-offs they've made to avoid burnout. The specifics involved naming two things they've deliberately given up. The details are personal, but the act of sharing them publicly is the strategic move worth noting.
Marco: This is founder-as-brand-asset thinking, and it works particularly well in wellness because the category runs on credibility. Consumers aren't just buying a product — they're buying into a belief system. When the founder visibly lives that system, the whole brand proposition becomes more coherent. In European markets, where consumers are quicker to distrust polished corporate messaging, that kind of unfiltered personal narrative travels well.
Klara: My hesitation is about the line between authenticity and theatre. Sharing a wellness routine at a major conference, for an audience of thousands, is a curated act. I don't doubt these founders believe what they're saying. But the moment personal wellbeing becomes a communications strategy, it's performing authenticity — not just practising it. Audiences in mature markets will notice that distinction.
Marco: That tension is worth sitting with. The brands that navigate it best will be the ones where the founder story is consistent over time — not just deployed at moments of peak visibility. Longevity is the test.
Marco: The biggest commercial lesson today is simple — your claims are your biggest asset, and your biggest liability.
Klara: Back every claim with evidence you can defend in front of a regulator, not just a consumer.
Marco: Science, compliance, and brand story — when those three align, you build something that actually lasts.